The pool, Atlas Venture Fund IX LP, closed earlier this month. The fund came in above its $250 million target, the person said.
Atlas’ last fund collected $283 million in 2009.
News of the fundraising comes as the Boston VC announced Thursday that Amgen Ventures and Novartis are new LPs of fund IX.
“Amgen is very excited to partner with Atlas Venture, one of a small number of venture capital groups that truly focuses on creating value by translating groundbreaking science into new companies,” Sean Harper, M.D., Amgen’s EVP of Research and Development, said in a statement.
Atlas is an early stage VC that invests in technology and life sciences, mostly biotech. The firm said it expects Fund IX to “create and/or fund more than fifteen new biotech companies.”
Image courtesy of Shutterstock.